Actively Recruiting

All Genders
NCT03141021

Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

Led by Washington University School of Medicine · Updated on 2026-03-09

1050

Participants Needed

13

Research Sites

1878 weeks

Total Duration

On this page

Sponsors

W

Washington University School of Medicine

Lead Sponsor

B

Boston Children's Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established, collecting, in a standardized manner, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from centers worldwide with expertise in these NF1-related cancers. Although retrospective in nature, the resulting data from this registry may reveal previously unanticipated patterns, similar to the INFACT effort outcome. This registry would then allow the acquisition of data associated with MPNST biospecimens collected under associated banks (frozen or paraffin-embedded, germline (or normal tissue DNA) samples, and any previously somatic whole-exome or whole-genome sequencing data for aggregate analyses). Second, the investigators plan to co-register patients to institutional banks in order to prospectively collect MPNST samples for analysis. These patients will be consented in order to collect the above information and for banking of tumor tissue and future studies that include genomic characterization of the tumors.

CONDITIONS

Official Title

Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Any patient diagnosed with an MPNST is eligible for enrollment provided they or their legal guardian consent to participate.
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 13 locations

1

Moffitt Cancer Center

Tampa, Florida, United States, 33612

Completed

2

Johns Hopkins

Baltimore, Maryland, United States, 21205

Actively Recruiting

3

National Institutes of Health (NIH)

Bethesda, Maryland, United States, 20892

Not Yet Recruiting

4

Dana Farber Cancer Institute

Boston, Massachusetts, United States, 02215

Withdrawn

5

University of Minnesota

Minneapolis, Minnesota, United States, 55455

Withdrawn

6

Washington University School of Medicine

St Louis, Missouri, United States, 63110

Actively Recruiting

7

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

Not Yet Recruiting

8

Lifespan

Providence, Rhode Island, United States, 02903

Completed

9

University of Utah

Salt Lake City, Utah, United States, 84112

Completed

10

Mount Sinai

Toronto, Ontario, Canada, M5T 3L9

Actively Recruiting

11

Global Gene Corporation

Mumbai, India

Completed

12

Nagoya University Hospital

Nagoya, Showa Ward, Japan

Actively Recruiting

13

Royal National Orthopedic Hospital

London, United Kingdom

Terminated

Loading map...

Research Team

A

Angela Hirbe, M.D., Ph.D.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here